Skip to main content
Top
Published in: BMC Musculoskeletal Disorders 1/2024

Open Access 01-12-2024 | Femoral Fracture | Research

Therapeutic advantage of teriparatide in very elderly patients with proximal femoral fractures: a functional and BMD analysis

Authors: Ooi Chin Sheng, Wen-Tien Wu, Cheng-Huan Peng, Ting-Kuo Yao, Ing-Ho Chen, Jen-Hung Wang, Kuang-Ting Yeh

Published in: BMC Musculoskeletal Disorders | Issue 1/2024

Login to get access

Abstract

Background

Teriparatide, a recombinant parathyroid hormone, is pivotal in osteoporosis treatment, particularly in post-surgical recovery for hip fractures. This study investigates its efficacy in functional recovery post-hip fracture surgery in elderly patients, a demographic particularly susceptible to osteoporotic fractures.

Methods

In this retrospective cohort study, 150 elderly patients with proximal femoral fractures undergoing open reduction and internal fixation were enrolled. They were categorized into two groups: receiving 20 µg of daily teriparatide injections for 18 months and receiving standard antiresorptive medications during a 24-month follow-up. Detailed records of patient demographics, Fracture Risk Assessment Tool scores, and comorbidities were kept. Key outcomes, including bone mineral density (BMD) and functional scores (Barthel Index and Visual Analog Scale for hip pain), were evaluated at 3 and 24 months post-surgery.

Results

Out of the original cohort, 126 patients (20 men and 106 women with an average age of 85.5 ± 9.3 years) completed the study. The teriparatide group exhibited significant enhancements in both functional scores and BMD when compared to the control group. Notably, functional improvements were less pronounced in male patients compared to female patients. Additionally, the incidence of new fractures was markedly lower in the teriparatide group.

Conclusion

Administering teriparatide daily for 18 months post-surgery for proximal femoral fractures significantly benefits very elderly patients by improving functionality and bone density, with observed differences in recovery between genders. These results reinforce the efficacy of teriparatide as a potent option for treating osteoporosis-related fractures in the elderly and highlight the importance of considering gender-specific treatment and rehabilitation strategies.
Literature
2.
go back to reference Galvano A, Gristina V, Scaturro D, Bazan Russo TD, Tomasello S, Vitagliani F, et al. The role of bone modifying agents for secondary osteoporosis prevention and pain control in post-menopausal osteopenic breast cancer patients undergoing adjuvant aromatase inhibitors. Front Endocrinol (Lausanne). 2023;14:1297950.CrossRefPubMed Galvano A, Gristina V, Scaturro D, Bazan Russo TD, Tomasello S, Vitagliani F, et al. The role of bone modifying agents for secondary osteoporosis prevention and pain control in post-menopausal osteopenic breast cancer patients undergoing adjuvant aromatase inhibitors. Front Endocrinol (Lausanne). 2023;14:1297950.CrossRefPubMed
3.
go back to reference Pisani P, Renna MD, Conversano F, Casciaro E, Di Paola M, Quarta E, et al. Major osteoporotic fragility fractures: risk factor updates and societal impact. World J Orthop. 2016;7:171–81.CrossRefPubMedPubMedCentral Pisani P, Renna MD, Conversano F, Casciaro E, Di Paola M, Quarta E, et al. Major osteoporotic fragility fractures: risk factor updates and societal impact. World J Orthop. 2016;7:171–81.CrossRefPubMedPubMedCentral
4.
go back to reference Rojas LGP, Cervantes REL, Almejo LL, Pesciallo CA, Garabano G, Bidolegui F, et al. Fragility fracture systems, Latin America perspective. OTA Int. 2022;5(3 Suppl):e178.CrossRefPubMedPubMedCentral Rojas LGP, Cervantes REL, Almejo LL, Pesciallo CA, Garabano G, Bidolegui F, et al. Fragility fracture systems, Latin America perspective. OTA Int. 2022;5(3 Suppl):e178.CrossRefPubMedPubMedCentral
5.
go back to reference van Eck CF, Klein CM, Rahmi H, Scheidt KB, Schultzel M, Lee BK, et al. Morbidity, mortality and cost of osteoporotic fractures—should proximal humerus fractures be taken as seriously as hip fractures? Ann Joint. 2019;4:3. van Eck CF, Klein CM, Rahmi H, Scheidt KB, Schultzel M, Lee BK, et al. Morbidity, mortality and cost of osteoporotic fractures—should proximal humerus fractures be taken as seriously as hip fractures? Ann Joint. 2019;4:3.
6.
go back to reference Aguiar F, Guerra M, Ganhão S, Gonçalves D, Martins-Rocha T, Fereira RM, et al. THU0485 Predicting 1-year mortality after a fragility hip fracture – the experience of a fracture liaison service. Anna Rheum Dis. 2018;77:450–1. Aguiar F, Guerra M, Ganhão S, Gonçalves D, Martins-Rocha T, Fereira RM, et al. THU0485 Predicting 1-year mortality after a fragility hip fracture – the experience of a fracture liaison service. Anna Rheum Dis. 2018;77:450–1.
7.
go back to reference Minisola S, Cipriani C, Grotta GD, Colangelo L, Occhiuto M, Biondi P, et al. Update on the safety and efficacy of teriparatide in the treatment of osteoporosis. Ther Adv Musculoskelet Dis. 2019;11:1759720X19877994.CrossRefPubMedPubMedCentral Minisola S, Cipriani C, Grotta GD, Colangelo L, Occhiuto M, Biondi P, et al. Update on the safety and efficacy of teriparatide in the treatment of osteoporosis. Ther Adv Musculoskelet Dis. 2019;11:1759720X19877994.CrossRefPubMedPubMedCentral
8.
go back to reference Yang T, Feng C, Qu Y, Wang Q, Yang Y, Wang B, et al. Effect of teriparatide on quality of life in patients with postmenopausal osteoporosis: a retrospective cohort study. J Int Med Res. 2020;48:300060519876744.PubMed Yang T, Feng C, Qu Y, Wang Q, Yang Y, Wang B, et al. Effect of teriparatide on quality of life in patients with postmenopausal osteoporosis: a retrospective cohort study. J Int Med Res. 2020;48:300060519876744.PubMed
9.
go back to reference Sun Q, Zhen G, Li TP, Guo Q, Li Y, Su W, et al. Parathyroid hormone attenuates osteoarthritis pain by remodeling subchondral bone in mice. Elife. 2021;10:e66532.CrossRefPubMedPubMedCentral Sun Q, Zhen G, Li TP, Guo Q, Li Y, Su W, et al. Parathyroid hormone attenuates osteoarthritis pain by remodeling subchondral bone in mice. Elife. 2021;10:e66532.CrossRefPubMedPubMedCentral
10.
go back to reference Mulgund M, Beattie KA, Wong AK, Papaioannou A, Adachi JD. Assessing adherence to teriparatide therapy, causes of nonadherence and effect of adherence on bone mineral density measurements in osteoporotic patients at high risk for fracture. Ther Adv Musculoskelet Dis. 2009;1:5–11.CrossRefPubMedPubMedCentral Mulgund M, Beattie KA, Wong AK, Papaioannou A, Adachi JD. Assessing adherence to teriparatide therapy, causes of nonadherence and effect of adherence on bone mineral density measurements in osteoporotic patients at high risk for fracture. Ther Adv Musculoskelet Dis. 2009;1:5–11.CrossRefPubMedPubMedCentral
13.
go back to reference MAHONEY FI, BARTHEL DW. FUNCTIONAL EVALUATION: THE BARTHEL INDEX. Md. State Med J. 1965;14:61–5. MAHONEY FI, BARTHEL DW. FUNCTIONAL EVALUATION: THE BARTHEL INDEX. Md. State Med J. 1965;14:61–5.
14.
go back to reference Koudouna S, Evangelopoulos DS, Sarantis M, Chronopoulos E, Dontas IA, Pneumaticos S. The Effect of Postoperative Physical Therapy following hip fracture: a Literature Review. Cureus. 2023;15:e37676.PubMedPubMedCentral Koudouna S, Evangelopoulos DS, Sarantis M, Chronopoulos E, Dontas IA, Pneumaticos S. The Effect of Postoperative Physical Therapy following hip fracture: a Literature Review. Cureus. 2023;15:e37676.PubMedPubMedCentral
15.
go back to reference Iolascon G, Paoletta M, Liguori S, Gimigliano F, Moretti A. Bone fragility: conceptual framework, therapeutic implications, and COVID-19-related issues. Ther Adv Musculoskelet Dis. 2022;14:1759720X221133429.CrossRefPubMedPubMedCentral Iolascon G, Paoletta M, Liguori S, Gimigliano F, Moretti A. Bone fragility: conceptual framework, therapeutic implications, and COVID-19-related issues. Ther Adv Musculoskelet Dis. 2022;14:1759720X221133429.CrossRefPubMedPubMedCentral
16.
go back to reference Chotiyarnwong P, McCloskey E, Eastell R, McClung MR, Gielen E, Gostage J, et al. A pooled analysis of fall incidence from placebo-controlled trials of Denosumab. J Bone Min Res. 2020;35:1014–21.CrossRef Chotiyarnwong P, McCloskey E, Eastell R, McClung MR, Gielen E, Gostage J, et al. A pooled analysis of fall incidence from placebo-controlled trials of Denosumab. J Bone Min Res. 2020;35:1014–21.CrossRef
17.
go back to reference Scaturro D, Rizzo S, Sanfilippo V, Giustino V, Messina G, Martines F, et al. Effectiveness of rehabilitative intervention on Pain, Postural Balance, and quality of life in women with multiple vertebral fragility fractures: a prospective cohort study. J Funct Morphol Kinesiol. 2021;6:24.CrossRefPubMedPubMedCentral Scaturro D, Rizzo S, Sanfilippo V, Giustino V, Messina G, Martines F, et al. Effectiveness of rehabilitative intervention on Pain, Postural Balance, and quality of life in women with multiple vertebral fragility fractures: a prospective cohort study. J Funct Morphol Kinesiol. 2021;6:24.CrossRefPubMedPubMedCentral
18.
go back to reference Dempster DW, Zhou H, Recker RR, Brown JP, Recknor CP, Lewiecki EM, et al. Differential effects of teriparatide and denosumab on intact PTH and bone formation indices: AVA osteoporosis study. J Clin Endocrinol Metab. 2016;101:1353–63.CrossRefPubMedPubMedCentral Dempster DW, Zhou H, Recker RR, Brown JP, Recknor CP, Lewiecki EM, et al. Differential effects of teriparatide and denosumab on intact PTH and bone formation indices: AVA osteoporosis study. J Clin Endocrinol Metab. 2016;101:1353–63.CrossRefPubMedPubMedCentral
19.
go back to reference Graeff C, Chevalier Y, Charlebois M, Varga P, Pahr D, Nickelsen TN, et al. Improvements in vertebral body strength under teriparatide treatment assessed in vivo by finite element analysis: results from the EUROFORS study. J Bone Min Res. 2009;24:1672–80.CrossRef Graeff C, Chevalier Y, Charlebois M, Varga P, Pahr D, Nickelsen TN, et al. Improvements in vertebral body strength under teriparatide treatment assessed in vivo by finite element analysis: results from the EUROFORS study. J Bone Min Res. 2009;24:1672–80.CrossRef
20.
go back to reference Lindsay R, Scheele WH, Neer R, Pohl G, Adami S, Mautalen C, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med. 2004;164:2024–30.CrossRefPubMed Lindsay R, Scheele WH, Neer R, Pohl G, Adami S, Mautalen C, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med. 2004;164:2024–30.CrossRefPubMed
21.
go back to reference Malouf-Sierra J, Tarantino U, García-Hernández PA, Corradini C, Overgaard S, Stepan JJ, et al. Effect of teriparatide or Risedronate in Elderly patients with a recent pertrochanteric hip fracture: final results of a 78-Week randomized clinical trial. J Bone Min Res. 2017;32:1040–51.CrossRef Malouf-Sierra J, Tarantino U, García-Hernández PA, Corradini C, Overgaard S, Stepan JJ, et al. Effect of teriparatide or Risedronate in Elderly patients with a recent pertrochanteric hip fracture: final results of a 78-Week randomized clinical trial. J Bone Min Res. 2017;32:1040–51.CrossRef
22.
go back to reference Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018;391:230–40.CrossRefPubMed Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018;391:230–40.CrossRefPubMed
23.
go back to reference Chen CH, Elsalmawy AH, Ish-Shalom S, Lim SJ, AlAli NS, Cunha-Borges JL, et al. The Effect of Teriparatide Treatment on the risk of Fragility fractures in Postmenopausal Women with osteoporosis: results from the Asian and Latin America Fracture Observational Study (ALAFOS). Calcif Tissue Int. 2022;110:74–86.CrossRefPubMed Chen CH, Elsalmawy AH, Ish-Shalom S, Lim SJ, AlAli NS, Cunha-Borges JL, et al. The Effect of Teriparatide Treatment on the risk of Fragility fractures in Postmenopausal Women with osteoporosis: results from the Asian and Latin America Fracture Observational Study (ALAFOS). Calcif Tissue Int. 2022;110:74–86.CrossRefPubMed
24.
go back to reference Kim SJ, Park HS, Lee DW, Lee JW. Short-term daily teriparatide improve postoperative functional outcome and fracture healing in unstable intertrochanteric fractures. Injury. 2019;50:1364–70.CrossRefPubMed Kim SJ, Park HS, Lee DW, Lee JW. Short-term daily teriparatide improve postoperative functional outcome and fracture healing in unstable intertrochanteric fractures. Injury. 2019;50:1364–70.CrossRefPubMed
25.
go back to reference Wu TC, Tsou YJ, Wu WT, Lee RP, Wang JH, Yeh KT. Five-year outcomes of continuous treatment with Zoledronic Acid Versus Denosumab in older men with high fracture risk: risk factor analysis of bone density improvement and incidence of New Fracture. J Clin Pharmacol. 2023. https://doi.org/10.1002/jcph.2378. Online ahead of print.CrossRefPubMed Wu TC, Tsou YJ, Wu WT, Lee RP, Wang JH, Yeh KT. Five-year outcomes of continuous treatment with Zoledronic Acid Versus Denosumab in older men with high fracture risk: risk factor analysis of bone density improvement and incidence of New Fracture. J Clin Pharmacol. 2023. https://​doi.​org/​10.​1002/​jcph.​2378. Online ahead of print.CrossRefPubMed
26.
go back to reference Qaseem A, Forciea MA, McLean RM, Denberg TD, Clinical Guidelines Committee of the American College of Physicians, Barry MJ, et al. Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice Guideline Update from the American College of Physicians. Ann Intern Med. 2017;166:818–39.CrossRefPubMed Qaseem A, Forciea MA, McLean RM, Denberg TD, Clinical Guidelines Committee of the American College of Physicians, Barry MJ, et al. Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice Guideline Update from the American College of Physicians. Ann Intern Med. 2017;166:818–39.CrossRefPubMed
27.
go back to reference Novak JR, Peak T, Gast J, Arnell M. Associations between masculine norms and health-care utilization in highly religious, heterosexual men. Am J Mens Health. 2019;13:1557988319856739.CrossRefPubMedPubMedCentral Novak JR, Peak T, Gast J, Arnell M. Associations between masculine norms and health-care utilization in highly religious, heterosexual men. Am J Mens Health. 2019;13:1557988319856739.CrossRefPubMedPubMedCentral
28.
29.
go back to reference Fahrleitner-Pammer A, Langdahl BL, Marin F, Jakob F, Karras D, Barrett A, et al. Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS). Osteoporos Int. 2011;22:2709–19.CrossRefPubMed Fahrleitner-Pammer A, Langdahl BL, Marin F, Jakob F, Karras D, Barrett A, et al. Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS). Osteoporos Int. 2011;22:2709–19.CrossRefPubMed
30.
go back to reference Silverman S, Langdahl BL, Fujiwara S, Saag K, Napoli N, Soen S, et al. Reduction of hip and other fractures in patients receiving teriparatide in real-world clinical practice: Integrated Analysis of four prospective observational studies. Calcif Tissue Int. 2019;104:193–200.CrossRefPubMed Silverman S, Langdahl BL, Fujiwara S, Saag K, Napoli N, Soen S, et al. Reduction of hip and other fractures in patients receiving teriparatide in real-world clinical practice: Integrated Analysis of four prospective observational studies. Calcif Tissue Int. 2019;104:193–200.CrossRefPubMed
Metadata
Title
Therapeutic advantage of teriparatide in very elderly patients with proximal femoral fractures: a functional and BMD analysis
Authors
Ooi Chin Sheng
Wen-Tien Wu
Cheng-Huan Peng
Ting-Kuo Yao
Ing-Ho Chen
Jen-Hung Wang
Kuang-Ting Yeh
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Musculoskeletal Disorders / Issue 1/2024
Electronic ISSN: 1471-2474
DOI
https://doi.org/10.1186/s12891-024-07373-6

Other articles of this Issue 1/2024

BMC Musculoskeletal Disorders 1/2024 Go to the issue